Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CCR5 receptor antagonist

DRUG CLASS:

CCR5 receptor antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

5P12-RANTES (0)

5P12-RANTES (0)

›

MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab + maraviroc Sensitive: C3 – Early Trials pembrolizumab + maraviroc Sensitive : C3	pembrolizumab + maraviroc Sensitive: C3 – Early Trials pembrolizumab + maraviroc Sensitive : C3
CCR5 positive	Triple Negative Breast Cancer	CCR5 positive	Triple Negative Breast Cancer	leronlimab Sensitive: C3 – Early Trials leronlimab Sensitive : C3	leronlimab Sensitive: C3 – Early Trials leronlimab Sensitive : C3
CCL5 overexpression	Glioblastoma	CCL5 overexpression	Glioblastoma	maraviroc Sensitive: D – Preclinical maraviroc Sensitive : D	maraviroc Sensitive: D – Preclinical maraviroc Sensitive : D